Main to remember
- Eli Lilly’s actions jumped 16% Thursday morning after the pharmaceutical company published the results of phase 3 trial for its oral weight loss medication which “demonstrated statistically significant efficacy results and a safety profile in accordance with injectable GLP-1 drugs.
- The pill has achieved its objectives of reduction of the marker of A1C diabetes and weight loss.
- The trial is the first of the seven for the medication, and Eli Lilly plans to submit it for the approval of the FDA next year.
The actions of Eli Lilly (Lly) jumped 16% Thursday morning to direct the winners of the S&P 500 after the pharmaceutical company has published clinical trial results for its oral weight loss drug which “demonstrated statistically significant efficacy results and a safety profile in accordance with injectable GLP-1 drugs”.
The first of the seven phase 3 trials for Orforglipron showed that it was more effective than a placebo to cause weight loss and a reduction in A1C, a long -term blood sugar metric used to assess diabetes treatments, said Lilly. Weight and A1C reductions have increased for patients taking higher doses of the drug.
The medication has had gastrointestinal side effects similar to the injectable weight loss drugs of Eli Lilly Mounjaro and Zepbound, including nausea, indigestion and diarrhea. The rate of patients reporting side effects also varied from a dose depending on the different doses, which concerns 10% to 26% of patients.
Eli Lilly said she was planning to present data at a conference and in a peer -evaluated newspaper. The results of other trials for Orforglipron will be published later this year, and the company plans to file a request for approval of the Food and Drug Administration (FDA) as a treatment of type 2 diabetes in 2026.
Lilly, Rival Novo Nordisk (NVO), and others are in the development of new weight loss treatments which can be taken orally rather than injects. Pfizer (PFE) interrupted a test of oral medication earlier this week after a patient reported a liver injury.
While Eli Lilly Share has climbed on the news, those of Novo Nordisk – the manufacturer of successful drugs Ozempic and Wegovy – broke 7% shortly after the opening bell.
Update – This article has been updated with the latest information on the course of action
Tradingview
